Treatments for hair loss represent the second largest segment of aesthetic procedures performed in the United States.  There are over 70 million Americans that suffer from hair loss and hair miniaturization with of 20 million being female.  The new treatment options for alopecia, PCOS, and endocrine system changes allow for the reversal and correction of hair loss for a majority of your patients.  New technology, Platelet Rich Plasma, Biologics (amniotic tissue), Red LED Light Therapies, and new physician only topical prescriptions give patients and physicians options for the correction and reversal of hair loss and hair thinning.

Hair loss treatment therapies are expected to keep growing through 2026 as the number of men and women increases based on population trends (aging population), knowledge of treatment options (patient education), growing discretionary income, and the emphasis by newer generations on their outward appearances.  Hair loss amongst men is about 58% and with perimenopausal women there is a 25% chance of hair shedding.  The psychosocial issues associated with hair loss has real importance tp patients who are actively seeking treatments and solutions. Though many forms of hair loss have a hereditary component it does not affect the newer forms of prevention and treatment that give correction and reversal of hair loss in both men and women.

Overall medical (non-surgical) hair loss treatments represent a very large percentage of the market but are very fragmented with small private practices. Annual revenue exceeds $3.5B and is expected to grow 5.7% each year through 2025.

The American Academy of Procedural Medicine (AAOPM) Hair Loss Treatment Therapy Training will instruct you in the latest individual and combination therapies including various mechanical, prescription, and biological treatment options (PRP, LED light therapies, biologics) including the use of supplements.  The instruction will include the latest science for physicians to fully understand the pathophysiology for hair growth, hair loss, and proper identification and cause for the alopecia. The latest evidenced based scientific data is presented such as gene expression, stem cell markers/receptors, hormonal considerations, growth factors, and other data to provide evidenced based information to the efficacy and rationale for treatments.

Differences between men and women are discussed throughout the program as the reasoning for their hair loss and patterns of alopecia are not the same.  Men typically have “hair miniaturization” that relates to excessive conversion of DHT that damages the hair follicle over time and allows for early ejection (catagen stage) of the hair and the hair will grow miniaturized over a period of time until the hair is dormant.  Over a period of time this dormancy will not allow a new hair to grow and fibrosis of tissue will take place and why early detection of hair loss is important as it does become progressive.

Female hair loss and female pattern baldness is increasing among newer generations most likely due to environmental issues.  Typical female hair loss is defined as “hair shedding” where there is rapid ejection of the existing hair due to changes to the endocrine system and/or conditions such as PCOS.  Other hormonal factors, interaction with certain drugs, and other health issues affecting thinning hair and shedding and complete protocols for the diagnostic testing of these various scenarios are given at the program. Bottom line is that the loss of hair and hair thinning is multi-factorial and combination treatments should always be considered and in determining the pathways for treatment.

See full article at